A slice of data from the third clinical trial for Gilead's remdesivir indicates that the experimental therapy is somewhat effective in treating COVID-19 patients -- but is not the silver bullet that had been hoped for. $GIL
A slice of data from the third clinical trial for Gilead Sciences Inc.’s remdesivir indicates that the experimental therapy is somewhat effective in treating COVID-19 patients but is not the silver bullet that had been hoped for.
The results found that the drug is more effective in patients who received a five-day regimen than those who took the drug for twice as long or those on the standard of care, based on one endpoint: clinical improvement by day 11. The full clinical trial data is expected to be published at a later date.The design of the trial has also raised eyebrows among some analysts and pharmaceutical experts.
Gilead previously shared data from an open-label, Phase 3 clinical study evaluating remdesivir in severely ill patients, as did the National Institute of Allergy and Infectious Diseases from a randomized, placebo-controlled study of the drug. Both data sets were used to inform the Food and Drug Administration’s decision on May 1 to grant emergency use authorization to remdesivir for certain very ill COVID-19 patients.
Today’s numbers:Coronavirus update: Global case tally tops 6 million as weekend protests spark concerns they will lead to an increase in infections
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Gilead slides 4% after coronavirus drug shows limited benefit in moderately ill patients - Business InsiderBusiness Insider is a fast-growing business site with deep financial, media, tech, and other industry verticals. Launched in 2007, the site is now the largest business news site on the web.
Weiterlesen »
Gilead says remdesivir helped moderate COVID-19 patients improveGilead Sciences Inc said on Monday its antiviral drug remdesivir showed improvement in patients with moderate COVID-19 in a late-stage study.
Weiterlesen »
Gilead says new data shows remdesivir coronavirus treatment helped moderately sick patients
Weiterlesen »
Gilead trades that made millions on COVID-19 drug news raise eyebrowsWell-timed trades in Gilead Sciences Inc's options ahead of good news on the biopharmaceutical company's COVID-19 drug treatment may draw regulatory scrutiny, experts said.
Weiterlesen »
Gilead says new data shows remdesivir coronavirus treatment helped moderately sick patients
Weiterlesen »
Gilead says remdesivir helped moderate COVID-19 patients improveGilead Sciences Inc said on Monday its antiviral drug remdesivir showed improvement in patients with moderate COVID-19 in a late-stage study.
Weiterlesen »